Rigel Pharmaceuticals, Inc.
Compositions and methods for inhibition of the JAK pathway

Last updated:

Abstract:

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

Status:
Grant
Type:

Utility

Filling date:

24 May 2018

Issue date:

11 Feb 2020